BR9712874A - Proteìnas solúveis - Google Patents

Proteìnas solúveis

Info

Publication number
BR9712874A
BR9712874A BR9712874-0A BR9712874A BR9712874A BR 9712874 A BR9712874 A BR 9712874A BR 9712874 A BR9712874 A BR 9712874A BR 9712874 A BR9712874 A BR 9712874A
Authority
BR
Brazil
Prior art keywords
protein
native protein
proteins
soluble
native
Prior art date
Application number
BR9712874-0A
Other languages
English (en)
Inventor
Stanley B Prusiner
Fred E Cohen
Tamaki Muramoto
Original Assignee
Tthe University Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tthe University Of California filed Critical Tthe University Of California
Publication of BR9712874A publication Critical patent/BR9712874A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Non-Silver Salt Photosensitive Materials And Non-Silver Salt Photography (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Bipolar Transistors (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Detergent Compositions (AREA)

Abstract

<B>PROTEìNAS SOLúVEIS<D>. A invenção inclui deletar segmentos de códon a partir de DNA exprimindo uma proteína nativa com a finalidade de obter uma proteína solúvel, mais curta a qual imita as características de uma proteína nativa insolúvel. Proteínas solúveis da invenção são caracterizadas por: (1) ter menos amino ácidos do que a proteína nativa de comprimento total; (2) ter um grau superior de solubilidade do que a proteína nativa; (3) reter as características biológicas básicas da proteína nativa tal como (a) não estar sujeita à digestão enzimática e (b) causar doença. Proteínas solúveis da invenção são obtidas mediante provisão de uma seq³ência de DNA a qual codifica uma proteína nativa e removendo sistematicamente códons, fazendo cópias das versões reduzidas de DNA as quais são então exprimidas para proporcionar as proteínas reduzidas. As proteínas reduzidas são então testadas em termos de solubilidade. Proteínas solúveis são então testadas adicionalmente para confirmar que as mesmas retêm as características biológicas da proteína nativa.
BR9712874-0A 1996-11-05 1997-04-15 Proteìnas solúveis BR9712874A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/740,947 US5834593A (en) 1996-11-05 1996-11-05 Soluble form of PrPSC which is insoluble in native form
PCT/US1997/006227 WO1998020022A1 (en) 1996-11-05 1997-04-15 Soluble proteins

Publications (1)

Publication Number Publication Date
BR9712874A true BR9712874A (pt) 2000-02-01

Family

ID=24978724

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9712874-0A BR9712874A (pt) 1996-11-05 1997-04-15 Proteìnas solúveis

Country Status (13)

Country Link
US (1) US5834593A (pt)
EP (1) EP1012162B1 (pt)
JP (1) JP2001506979A (pt)
AT (1) ATE227736T1 (pt)
AU (1) AU720533B2 (pt)
BR (1) BR9712874A (pt)
CA (1) CA2268354A1 (pt)
DE (1) DE69717167T2 (pt)
DK (1) DK1012162T3 (pt)
ES (1) ES2186886T3 (pt)
NZ (1) NZ335103A (pt)
PT (1) PT1012162E (pt)
WO (1) WO1998020022A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2758337B1 (fr) * 1997-01-14 1999-03-05 Commissariat Energie Atomique Methode de criblage de substances a action therapeutique dans le traitement des esst comprenant une etape d'isolement de la prpres, a partir de la rate, procede d'isolement de le prpres et ses applications
GB2348203B (en) 1998-11-04 2002-06-19 Imp College Innovations Ltd Solube beta-forms of prion proteins, methods of preparation and use
US6166187A (en) * 1999-03-05 2000-12-26 The Regents Of The University Of California Method of concentrating prion proteins in blood samples
DE19918141A1 (de) * 1999-04-21 2000-10-26 Boehringer Ingelheim Vetmed Verfahren zur Diagnose von übertragbaren Spongiformen Enzephalopathien
US6437102B1 (en) 1999-11-24 2002-08-20 Bayer Corporation Method of separating prions from biological materials
AU2002258646A1 (en) * 2001-03-30 2002-10-15 Texas A And M University System Transgenic animals resistant to transmissible spongiform encephalopathies
GB0419628D0 (en) * 2004-09-03 2004-10-06 European Molecular Biology Lab Embl Method for determining protein solubility

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013720A (en) * 1986-05-06 1991-05-07 Abbott Laboratories SAP-6-Val proteins and methods
US5266684A (en) * 1988-05-02 1993-11-30 The Reagents Of The University Of California Peptide mixtures
JP2750220B2 (ja) * 1989-07-21 1998-05-13 ワシントン ユニバーシティ 組換え産生したヒト細胞膜補助因子タンパク（ｍｃｐ）
US5182366A (en) * 1990-05-15 1993-01-26 Huebner Verena D Controlled synthesis of peptide mixtures using mixed resins
ATE288484T1 (de) * 1991-11-14 2005-02-15 Charles Weissmann Transgene nicht-menschliche tiere ohne prionprotein
AU4376093A (en) * 1992-05-15 1993-12-13 Instituto Nazionale Neurologico C. Besta Soluble prion polypeptides, and methods for detecting and purifying thereof
US5605691A (en) * 1992-09-17 1997-02-25 Ophidian Pharmaceuticals, Inc. Immunologically active proteins from inclusion bodies
US5565186A (en) * 1994-05-13 1996-10-15 The Regents Of The University Of California Method of detecting prions in a sample and transgenic animal used for same

Also Published As

Publication number Publication date
EP1012162A4 (en) 2000-06-28
WO1998020022A1 (en) 1998-05-14
ATE227736T1 (de) 2002-11-15
JP2001506979A (ja) 2001-05-29
AU2669497A (en) 1998-05-29
AU720533B2 (en) 2000-06-01
EP1012162A1 (en) 2000-06-28
DK1012162T3 (da) 2003-03-10
CA2268354A1 (en) 1998-05-14
PT1012162E (pt) 2003-04-30
ES2186886T3 (es) 2003-05-16
DE69717167D1 (de) 2002-12-19
EP1012162B1 (en) 2002-11-13
US5834593A (en) 1998-11-10
DE69717167T2 (de) 2003-07-24
NZ335103A (en) 2000-10-27

Similar Documents

Publication Publication Date Title
Kang et al. Characterization of the cyanogen bromide peptides from the α1 chain of chick skin collagen
Ludueña et al. Identification of the phosphorylated β‐tubulin isotype in differentiated neuroblastoma cells
Mortarino et al. Two‐dimensional polyacrylamide gel electrophoresis map of bull seminal plasma proteins
AR000610A1 (es) Un método para la expresión de un polipéptido recombinante por una célula huésped
Tuross et al. [9] Ancient proteins in fossil bones
ATE96447T1 (de) Verfahren zur isolierung basischer proteine aus proteingemischen.
ATE367398T1 (de) Verfahren zur rückfaltung von proteinen mit freien cysteinresten
DK1218504T3 (da) GL50 molekyler og anvendelser deraf
DK1005540T3 (da) IKK-beta-proteiner, nukleinsyrer og fremgangsmåder
EA200000109A1 (ru) Химерный белок растворимого рецептора интерлейкина-6/лиганда, его аналоги и способы применения
EP2311955A3 (en) Osteoprotegerin binding proteins and their receptors
ES2032378T3 (es) Procedimiento para preparar una proteina de fusion.
WO2001073059A3 (en) 38692 and 21117: dual specificity phosphatase molecules and uses therefor
ATE451390T1 (de) Polypeptide zur bindung an das b-lymphozyten- stimulatorische protein (blys)
DE60041243D1 (de) Gebrauchsverfaheren eines neuen lysyloxidase-verwandten proteins
DK1012162T3 (da) Opløselige proteiner
FR2816410B1 (fr) Necessaire de detection de la proteine esm-1 et procede de detection mettant en oeuvre ledit necessaire
DE68925275D1 (de) Endotoxin-bindeprotein und dessen verwendung
Yoshiya et al. Development of trityl group anchored solubilizing tags for peptide and protein synthesis
EP1576157A4 (en) FLUORESCENCE PROTEINS FROM COPEPODA SPECIES AND METHOD FOR USE THEREOF
Nakamura et al. Tailored synthesis of 162‐residue S‐monoglycosylated GM2‐activator protein (GM2AP) analogues that allows facile access to a protein library
DE60142356D1 (de) 18480 humane proteinkinasemoleküle und ihre verwendungen
SATO et al. Isolation of intact type V collagen from fish intramuscular connective tissue
DE60233347D1 (de) Schnellreifende fluoreszierende proteine und verfahren zu deren anwendung
ATE433489T1 (de) 16836, ein mitglied der humanen phospholipase c familie und seine verwendungen

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 7A,8A, 9A E 10A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1908 DE 31/07/2007.